Suven Life Sciences (Suven), a Hyderabad-based biopharmaceutical company, has received four product patents, two from Australia and two from Canada for the New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

According to a Suven press release, the two Australian patent nos 2007343062 and 2008246947 & Canadian patent nos 2,490,254 and 2,552,106 are valid through 2027 and 2028 respectively.

The granted claims of the patents include the class of selective 5-HT compounds discovered by the company and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, Attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.

“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for cognitive disorders with high unmet medical need and an estimated $30 billion market potential globally,” said Venkat Jasti, CEO,  Suven.

With these new patents, Suven has a total of thirteen granted patents from Australia, and eight granted patents from Canada. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at phase-I or phase-ll.